Literature DB >> 20848202

Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation.

Kishore Maganty1, David Levi, Jang Moon, Pablo A Bejarano, Leopoldo Arosemena, Andreas Tzakis, Paul Martin.   

Abstract

BACKGROUND: Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma is a rare hepatobiliary malignancy incorporating components derived from both hepatocyte and intrahepatic bile duct epithelium. The natural history, treatment, and prognosis of this distinct cancer differ from hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) and are not completely understood. There is considerable controversy about the classification, treatment, and survival, which in turn is related to the rarity of the condition. Treatment options include surgical resection and the prognosis is believed to be better than CC but worse than HCC alone.
METHODS: We report a single-center liver transplantation experience with the management of three patients with combined HCC-ICC with LT. Two patients were transplanted with presumed HCC within Milan criteria and the other patient was noted to have an incidental nodule in the explanted liver. Histomorphology and immunohistochemical studies revealed the presence of combined HCC-ICC in all three explants.
RESULTS: One patient died 144 days after LT due to metastatic tumor. The second patient is alive and is tumor free at 8.5 years post-LT, and the third patient died of metastatic tumor at 155 days after LT.
CONCLUSION: Good long-term survival can be achieved in at least some patients with this combined tumor type.

Entities:  

Mesh:

Year:  2010        PMID: 20848202     DOI: 10.1007/s10620-010-1402-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  28 in total

1.  Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging.

Authors:  G Lin; C-H Toh; R-C Wu; S-F Ko; S-H Ng; W-C Chou; J-H Tseng
Journal:  Int J Clin Pract       Date:  2007-05-30       Impact factor: 2.503

2.  Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Huai-Quan Zuo; Lu-Nan Yan; Yong Zeng; Jia-Ying Yang; Hong-Zhi Luo; Jiang-Wen Liu; Li-Xin Zhou
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2007-04

3.  Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Won-Suk Lee; Kwang-Woong Lee; Jin-Seok Heo; Sung-Ju Kim; Seong-Ho Choi; Yong-Il Kim; Jae-Won Joh
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

4.  Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features.

Authors:  Y Fukukura; J Taguchi; O Nakashima; Y Wada; M Kojiro
Journal:  J Comput Assist Tomogr       Date:  1997 Jan-Feb       Impact factor: 1.826

5.  Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.

Authors:  Di Tang; Hiroaki Nagano; Masato Nakamura; Hiroshi Wada; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Keizo Dono; Morito Monden
Journal:  J Gastrointest Surg       Date:  2006 Jul-Aug       Impact factor: 3.452

6.  Cholangiocarcinoma presenting with recurrent venous thrombosis.

Authors:  S K Bandyopadhyay; N Sarkar; S Ghosh; S Dasgupta
Journal:  J Assoc Physicians India       Date:  2003-08

Review 7.  Management of combined hepatocellular and cholangiocarcinoma.

Authors:  W T Kassahun; J Hauss
Journal:  Int J Clin Pract       Date:  2008-02-13       Impact factor: 2.503

8.  Combined hepatocellular and cholangiocarcinoma of the liver: sonography, CT, angiography, and iodized-oil CT with pathologic correlation.

Authors:  B I Choi; J K Han; Y I Kim; H C Kim; J H Park; C W Kim; M C Han
Journal:  Abdom Imaging       Date:  1994 Jan-Feb

9.  Hepatic artery thrombosis after adult liver transplantation.

Authors:  Barbara J Stange; Matthias Glanemann; Natascha C Nuessler; Utz Settmacher; Thomas Steinmüller; Peter Neuhaus
Journal:  Liver Transpl       Date:  2003-06       Impact factor: 5.799

10.  Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period.

Authors:  Natasha S Becker; Joel A Rodriguez; Neal R Barshes; Christine A O'Mahony; John A Goss; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2007-10-26       Impact factor: 3.452

View more
  12 in total

1.  Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C.

Authors:  Winston Dunn; Maura O'Neil; Jie Zhao; Chuang Hong Wu; Benjamin Roberts; Shweta Chakraborty; Craig Sherman; Brandy Weaver; Ryan Taylor; Jody Olson; Mojtaba Olyaee; Richard Gilroy; Timothy Schmitt; Yu-Jui Yvonne Wan; Steven A Weinman
Journal:  Hepatology       Date:  2013-12-23       Impact factor: 17.425

Review 2.  Liver cancer: Approaching a personalized care.

Authors:  Jordi Bruix; Kwang-Hyub Han; Gregory Gores; Josep Maria Llovet; Vincenzo Mazzaferro
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

3.  Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in a single patient: A case report.

Authors:  Rongxing Zhou; Minjia Zhang; Nansheng Cheng; Yong Zhou
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

Review 4.  Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review.

Authors:  Rahul Gupta; Junichi Togashi; Nobuhisa Akamatsu; Yoshihiro Sakamoto; Norihiro Kokudo
Journal:  Surg Today       Date:  2017-01-25       Impact factor: 2.549

Review 5.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

6.  Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital.

Authors:  Junichi Togashi; Nobuhisa Akamastu; Norihiro Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

Review 7.  Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine.

Authors:  Taizo Hibi; Masahiro Shinoda; Osamu Itano; Yuko Kitagawa
Journal:  Organogenesis       Date:  2014-05-16       Impact factor: 2.500

8.  Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.

Authors:  Leigh Anne Dageforde; Neeta Vachharajani; Parissa Tabrizian; Vatche Agopian; Karim Halazun; Erin Maynard; Kristopher Croome; David Nagorney; Johnny C Hong; David Lee; Cristina Ferrone; Erin Baker; William Jarnagin; Alan Hemming; Gabriel Schnickel; Shoko Kimura; Ronald Busuttil; Jessica Lindemann; Sander Florman; Matthew L Holzner; Rami Srouji; Marc Najjar; Lavanya Yohanathan; Jane Cheng; Hiral Amin; Charles A Rickert; Ju Dong Yang; Joohyun Kim; Jennifer Pasko; William C Chapman; Maria B Majella Doyle
Journal:  J Am Coll Surg       Date:  2020-12-13       Impact factor: 6.113

9.  Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?

Authors:  Xiaolong Wang; Wentao Wang; Xijuan Ma; Xin Lu; Shaodong Li; Mengsu Zeng; Kai Xu; Chun Yang
Journal:  Eur Radiol       Date:  2020-05-08       Impact factor: 5.315

Review 10.  Treatment of Combined Hepatocellular and Cholangiocarcinoma.

Authors:  Simona Leoni; Vito Sansone; Stefania De Lorenzo; Luca Ielasi; Francesco Tovoli; Matteo Renzulli; Rita Golfieri; Daniele Spinelli; Fabio Piscaglia
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.